#BEGIN_DRUGCARD DB01212

# AHFS_Codes:
08:12.06.12

# ATC_Codes:
J01DD04

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Biotrakson
Rocephine

# CAS_Registry_Number:
73384-59-5

# ChEBI_ID:
29007

# Chemical_Formula:
C18H18N8O7S3

# Chemical_IUPAC_Name:
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
657409

# Description:
A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]

# Dosage_Forms:
Powder, for solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Acenocoumarol	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of acenocoumarol.
Amikacin	Increased risk of nephrotoxicity
Anisindione	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione.
Calcium Acetate	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
Calcium Chloride	Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion.
Dicumarol	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol.
Gentamicin	Increased risk of nephrotoxicity
Kanamycin	Increased risk of nephrotoxicity
Neomycin	Increased risk of nephrotoxicity
Netilmicin	Increased risk of nephrotoxicity
Streptomycin	Increased risk of nephrotoxicity
Tobramycin	Increased risk of nephrotoxicity
Warfarin	The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-6.88

# Experimental_LogP_Hydrophobicity:
-1.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ceftriaxone

# HET_ID:
Not Available

# Half_Life:
5.8-8.7 hours

# InChI_Identifier:
InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1

# InChI_Key:
InChIKey=VAAUVRVFOQPIGI-SPQHTLEESA-N

# Indication:
For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

# KEGG_Compound_ID:
C06683

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1212

# Mechanism_Of_Action:
Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.

# Melting_Point:
>155 Â°C

# Molecular_Weight_Avg:
554.58

# Molecular_Weight_Mono:
554.04605704

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448866

# Pharmacology:
Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. Ceftriaxone has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ceftriaxone results from the inhibition of cell wall synthesis and is mediated through Ceftriaxone binding to penicillin binding proteins (PBPs). Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.

# Predicted_LogP_Hydrophobicity:
-0.01

# Predicted_LogS:
-3.7

# Predicted_Water_Solubility:
1.05e-01 g/l

# Primary_Accession_No:
DB01212

# Protein_Binding:
95%

# PubChem_Compound_ID:
5479530

# PubChem_Substance_ID:
46506458

# RxList_Link:
http://www.rxlist.com/cgi/generic3/ceftriax.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00395

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Cefatriaxone
Ceftriaxona [INN-Spanish]
Ceftriaxonum [INN-Latin]
Ceftriazone

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:00 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ceftriaxone

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
GLUL

# Phase_1_Metabolizing_Enzyme_1_ID:
3987

# Phase_1_Metabolizing_Enzyme_1_Name:
Glutamine synthetase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Glutamine synthetase
MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEW
NFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRI
MDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHY
RACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDP
KPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRL
TGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCL
LNETGDEPFQYKN

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P15104

# Drug_Target_1_Cellular_Location:
Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
20704258	Tomberg J, Unemo M, Davies C, Nicholas RA: Molecular and Structural Analysis of Mosaic Variants of Penicillin-Binding Protein 2 Conferring Decreased Susceptibility to Expanded-Spectrum Cephalosporins in Neisseria gonorrhoeae: Role of Epistatic Mutations. Biochemistry. 2010 Aug 25.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X16022

# Drug_Target_1_GenBank_ID_Protein:
984233

# Drug_Target_1_GeneCard_ID:
penA

# Drug_Target_1_Gene_Name:
penA

# Drug_Target_1_Gene_Sequence:
>2040 bp
ATGAGAAAATTTAACAGCCATTCGATTCCGATTCGGCTTAATTTATTGTTTTCAATCGTC
ATTTTACTCTTTATGACCATTATTGGTCGTTTGTTGTATATGCAGGTTTTCAACAAGGAT
TTTTACGAAAAAAAGCTAGCCTCAGCTAGTCAGACCAAGATTACAAGCAGTTCAGCCCGT
GGGGAAATTTATGATGCTAGTGGAAAACCTTTGGTAGAAAATACGTTAAAGCAGGTTGTT
TCCTTTACGCGTAGCAATAAAATGACGGCTACAGACTTAAAAGAAACAGCTAAAAAGTTA
CTGACTTATGTGAGCATCAGTTCTCCAAATTTGACAGAACGAGCTGGCGATTACTATTTG
GCTGATCCTGAAATCTATAAAAAAATAGTGGAAGCTCTCCCAAGCGAGAAACGCTTGGAT
TCAGATGGCAATCGTCTATCCGAATCAGAACTGTATAACAATGCGGTCGATAGTGTACAA
ACGAGTCAACTAAACTATACAGAGGATGAAAAGAAAGAAATCTATCTTTTTAGTCAGTTA
AATGCTGTTGGAAACTTTGCGACAGGAACCATTGCTACAGATCCTCTAAATGATTCTCAG
GTGGCTGTTATTGCCTCTATTTCAAAGGAGATGCCTGGCATTAGTATTTCTACTTCTTGG
GATAGAAAGGTTTTGGAAACTTCCCTTTCTTCTATAGTTGGGAGTGTATCCAGTGAAAAA
GCTGGTCTCCCAGCGGAAGAAGCAGAAGCCTATCTTAAAAAAGGCTATTCTCTAAATGAC
CGTGTAGGAACCTCCTATTTGGAAAAGCAATATGAAGAGACCTTACAAGGAAAACGCTCG
GTAAAAGAAATCCATCTGGATAAATATGGCAATATGGAAAGCGTGGATACAATTGAGGAA
GGTAGTAAGGGAAACAATATCAAACTGACCATTGATTTGGCTTTCCAAGATAGCGTGGAT
GCTTTACTGAAAAGTTATTTCAATTCTGAGCTAGAAAATGGTGGAGCCAAGTATTCTGAA
GGTGTCTATGCAGTCGCCCTTAACCCAAAAACAGGTGCGGTTTTGTCTATGTCAGGGATT
AAACATGACTTGAAAACGGGAGAGTTGACGCCTGATTCCTTGGGAACGGTAACCAATGTC
TTTGTTCCAGGTTCGGTTGTCAAGGCGGCGACCATCAGCTCAGGTTGGGAAAATGGAGTC
TTGTCAGGAAACCAGACCTTGACAGACCAGTCCATTGTCTTCCAAGGTTCAGCTCCCATC
AATTCTTGGTATACTCAGGCTTACGGTTCATTCCCTATCACAGCGGTCCAAGCTCTGGAG
TATTCATCAAATACCTATATGGTCCAAACAGCCTTAGGTCTTATGGGGCAAACCTATCAA
CCCAATATGTTTGTCGGCACCAGCAATCTAGAGTCTGCTATGGAGAAACTGCGTTCAACC
TTTGGCGAATATGGCTTGGGTACTGCGACAGGAATTGACCTACCAGATGAATCTACTGGA
TTTGTTCCCAAAGAGTATAGCTTTGCTAATTACATTACTAATGCCTTTGGGCAGTTTGAT
AACTATACGCCGATGCAGTTGGCTCAGTATGTAGCAACTATTGCAAATAATGGTGTTCGT
GTGGCTCCTCGTATTGTTGAAGGCATTTATGGTAATAATGATAAGGGAGGACTGGGTGAC
TTGATTCAGCAACTGCAACCGACAGAGATGAATAAGGTCAATATATCCGACTCCGATATG
AGCATCTTGCACCAAGGTTTTTATCAGGTTGCCCATGGTACTAGTGGATTGACAACTGGA
CGTGCCTTTTCAAATGGTGCCTTGGTATCCATTAGCGGAAAAACAGGTACAGCCGAAAGC
TATGTGGCAGATGGTCAGCAAGCAACCAATACCAATGCGGTGGCCTATGCCCCATCTGAT
AATCCCCAAATCGCTGTCGCAGTGGTCTTTCCTCATAATACCAATCTAACAAATGGTGTA
GGACCTTCCATTGCGCGTGACATTATCAATCTGTATCAAAAATACCATCCAATGAACTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
11544234	Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS, Estrem ST, Fritz L, Fu DJ, Fuller W, Geringer C, Gilmour R, Glass JS, Khoja H, Kraft AR, Lagace RE, LeBlanc DJ, Lee LN, Lefkowitz EJ, Lu J, Matsushima P, McAhren SM, McHenney M, McLeaster K, Mundy CW, Nicas TI, Norris FH, O'Gara M, Peery RB, Robertson GT, Rockey P, Sun PM, Winkler ME, Yang Y, Young-Bellido M, Zhao G, Zook CA, Baltz RH, Jaskunas SR, Rosteck PR Jr, Skatrud PL, Glass JI: Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001 Oct;183(19):5709-17.
2654541	Dowson CG, Hutchison A, Spratt BG: Extensive re-modelling of the transpeptidase domain of penicillin-binding protein 2B of a penicillin-resistant South African isolate of Streptococcus pneumoniae. Mol Microbiol. 1989 Jan;3(1):95-102.
2798106	Dowson CG, Hutchison A, Spratt BG: Nucleotide sequence of the penicillin-binding protein 2B gene of Streptococcus pneumoniae strain R6. Nucleic Acids Res. 1989 Sep 25;17(18):7518.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6121

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
73872.3

# Drug_Target_1_Name:
Penicillin-binding protein 2B

# Drug_Target_1_Number_of_Residues:
680

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2B
MRKFNSHSIPIRLNLLFSIVILLFMTIIGRLLYMQVLNKDFYEKKLASASQTKITSSSAR
GEIYDASGKPLVENTLKQVVSFTRSNKMTATDLKETAKKLLTYVSISSPNLTERQLADYY
LADPEIYKKIVEALPSEKRLDSDGNRLSESELYNNAVDSVQTSQLNYTEDEKKEIYLFSQ
LNAVGNFATGTIATDPLNDSQVAVIASISKEMPGISISTSWDRKVLETSLSSIVGSVSSE
KAGLPAEEAEAYLKKGYSLNDRVGTSYLEKQYEETLQGKRSVKEIHLDKYGNMESVDTIE
EGSKGNNIKLTIDLAFQDSVDALLKSYFNSELENGGAKYSEGVYAVALNPKTGAVLSMSG
IKHDLKTGELTPDSLGTVTNVFVPGSVVKAATISSGWENGVLSGNQTLTDQSIVFQGSAP
INSWYTQAYGSFPITAVQALEYSSNTYMVQTALGLMGQTYQPNMFVGTSNLESAMEKLRS
TFGEYGLGTATGIDLPDESTGFVPKEYSFANYITNAFGQFDNYTPMQLAQYVATIANNGV
RVAPRIVEGIYGNNDKGGLGDLIQQLQPTEMNKVNISDSDMSILHQGFYQVAHGTSGLTT
GRAFSNGALVSISGKTGTAESYVADGQQATNTNAVAYAPSDNPQIAVAVVFPHNTNLTNG
VGPSIARDIINLYQKYHPMN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P0A3M6

# Drug_Target_1_SwissProt_Name:
PBP2_STRR6

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
4.85

# Drug_Target_1_Transmembrane_Regions:
9-29

#END_DRUGCARD DB01212
